Gilead Sciences Total Assets 2006-2021 | GILD
Gilead Sciences total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Gilead Sciences total assets for the quarter ending September 30, 2021 were $67.098B, a 10.22% increase year-over-year.
- Gilead Sciences total assets for 2020 were $68.407B, a 11% increase from 2019.
- Gilead Sciences total assets for 2019 were $61.627B, a 3.22% decline from 2018.
- Gilead Sciences total assets for 2018 were $63.675B, a 9.4% decline from 2017.
Gilead Sciences Annual Total Assets
(Millions of US $) |
| 2020 |
$68,407 |
| 2019 |
$61,627 |
| 2018 |
$63,675 |
| 2017 |
$70,283 |
| 2016 |
$56,977 |
| 2015 |
$51,716 |
| 2014 |
$34,664 |
| 2013 |
$22,579 |
| 2012 |
$21,240 |
| 2011 |
$17,303 |
| 2010 |
$11,593 |
| 2009 |
$9,699 |
| 2008 |
$6,937 |
| 2007 |
$5,835 |
| 2006 |
$4,086 |
| 2005 |
$3,766 |
Gilead Sciences Quarterly Total Assets
(Millions of US $) |
| 2021-09-30 |
$67,098 |
| 2021-06-30 |
$67,984 |
| 2021-03-31 |
$67,492 |
| 2020-12-31 |
$68,407 |
| 2020-09-30 |
$60,878 |
| 2020-06-30 |
$55,934 |
| 2020-03-31 |
$59,741 |
| 2019-12-31 |
$61,627 |
| 2019-09-30 |
$59,146 |
| 2019-06-30 |
$63,210 |
| 2019-03-31 |
$62,837 |
| 2018-12-31 |
$63,675 |
| 2018-09-30 |
$64,305 |
| 2018-06-30 |
$65,355 |
| 2018-03-31 |
$65,381 |
| 2017-12-31 |
$70,283 |
| 2017-09-30 |
$64,662 |
| 2017-06-30 |
$60,263 |
| 2017-03-31 |
$57,701 |
| 2016-12-31 |
$56,977 |
| 2016-09-30 |
$56,609 |
| 2016-06-30 |
$49,980 |
| 2016-03-31 |
$47,765 |
| 2015-12-31 |
$51,716 |
| 2015-09-30 |
$50,637 |
| 2015-06-30 |
$39,167 |
| 2015-03-31 |
$38,321 |
| 2014-12-31 |
$34,664 |
| 2014-09-30 |
$28,844 |
| 2014-06-30 |
$31,206 |
| 2014-03-31 |
$28,078 |
| 2013-12-31 |
$22,579 |
| 2013-09-30 |
$22,468 |
| 2013-06-30 |
$22,624 |
| 2013-03-31 |
$22,212 |
| 2012-12-31 |
$21,240 |
| 2012-09-30 |
$20,964 |
| 2012-06-30 |
$20,502 |
| 2012-03-31 |
$19,950 |
| 2011-12-31 |
$17,303 |
| 2011-09-30 |
$12,640 |
| 2011-06-30 |
$12,694 |
| 2011-03-31 |
$12,987 |
| 2010-12-31 |
$11,593 |
| 2010-09-30 |
$11,456 |
| 2010-06-30 |
$10,497 |
| 2010-03-31 |
$10,696 |
| 2009-12-31 |
$9,699 |
| 2009-09-30 |
$8,937 |
| 2009-06-30 |
$8,387 |
| 2009-03-31 |
$7,520 |
| 2008-12-31 |
$6,937 |
| 2008-09-30 |
$6,974 |
| 2008-06-30 |
$6,517 |
| 2008-03-31 |
$5,879 |
| 2007-12-31 |
$5,835 |
| 2007-09-30 |
$5,318 |
| 2007-06-30 |
$4,826 |
| 2007-03-31 |
$4,615 |
| 2006-12-31 |
$4,086 |
| 2006-09-30 |
$5,299 |
| 2006-06-30 |
$5,180 |
| 2006-03-31 |
$4,037 |
| 2005-12-31 |
$3,766 |
| 2005-09-30 |
$2,919 |
| 2005-06-30 |
$2,688 |
| 2005-03-31 |
$2,369 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$86.352B |
$24.689B |
|
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
|
